Intest Res.  2010 Jun;8(1):63-69. 10.5217/ir.2010.8.1.63.

Clinical Experience of Thalidomide in the Treatment of Korean Patients with Intestinal Behcet's Disease: Pilot Experience in a Single Center

• Lee HJ
• Cheon JH
• Lee KJ
• Jang HW
• Jung KS
• Jung ES
• Lee JH
• Jeon SM
• Hong SP
• Kim TI
• Kim WH

• KMID: 1974732
• DOI: http://doi.org/10.5217/ir.2010.8.1.63

Abstract

Intestinal Behcet's disease (BD) often leads to severe complications, such as perforation or massive bleeding, and therefore is one of the major causes of morbidity and mortality. As thalidomide has been identified and its anti-inflammatory and immunomodulatory properties clarified, this drug has been used in cases of systemic BD with some success. Herein we report a case series of four patients with intestinal BD to share our clinical experience with thalidomide treatment. We studied the effects of thalidomide in four patients who had a chronic relapse of intestinal BD requiring the frequent use of systemic steroids due to refractoriness to prior treatments, such as 5-aminosalycylic acid and immunosuppressants. Pre- and post-treatment clinical and laboratory data, including clinical symptoms, laboratory data, disease activity index for intestinal BD, and thalidomide toxicity were recorded. Three of the four patients had a clinical and radiologic improvement after thalidomide treatment and all of the patients discontinued steroid therapy. Although two patients tolerated thalidomide, two patients could not continue the treatment because they suffered from edema and neutropenia. Thalidomide could be considered a therapeutic option for the treatment of intestinal BD.

Keyword

Behcet Syndrome; Gastrointestinal Disease; Thalidomide

MeSH Terms

Behcet Syndrome
Edema
Gastrointestinal Diseases
Hemorrhage
Humans
Immunosuppressive Agents
Neutropenia
Recurrence
Steroids
Thalidomide
Immunosuppressive Agents
Steroids
Thalidomide